Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration

Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration

Purpose To compare the 1‐year outcomes of treat‐and‐extend (TAE) and every‐other‐month (2M) regimens with intravitreal aflibercept in Japanese wet age‐related macular degeneration (AMD) patients. Methods Prospective, multicenter, randomized clinical trial. The primary outcome measure was the proport...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta ophthalmologica (Oxford, England) England), 2018-05, Vol.96 (3), p.e393-e398
Hauptverfasser: Haga, Akira, Kawaji, Takahiro, Ideta, Ryuichi, Inomata, Yasuya, Tanihara, Hidenobu
Format: Artikel
Sprache:eng
Schlagworte:
Acuity
aflibercept
age‐related macular degeneration
choroidal neovascularization
Macular degeneration
polypoidal choroidal vasculopathy
Retina
treat‐and‐extend
Visual acuity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose To compare the 1‐year outcomes of treat‐and‐extend (TAE) and every‐other‐month (2M) regimens with intravitreal aflibercept in Japanese wet age‐related macular degeneration (AMD) patients. Methods Prospective, multicenter, randomized clinical trial. The primary outcome measure was the proportion of eyes in which the best‐corrected visual acuity (BCVA) was maintained at week 52 [with a loss of
ISSN:1755-375X
1755-3768
DOI:10.1111/aos.13607